Cargando…

Experience with enteral sulfonylurea monotherapy for extremely low birth weight infants with hyperglycemia

Limited data are available on the effects of enteral sulfonylurea (SU) monotherapy in extremely low birth weight infants (ELBWIs) with hyperglycemia. Therefore, we report our experience with enteral SU monotherapy for hyperglycemic ELBWIs. We retrospectively evaluated 11 hyperglycemic ELBWIs (seven...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakagawa, Ai, Hirano, Daishi, Inage, Yuka, Yamada, Saya, Kotake, Yuko, Ikoma, Naohiro, Kumazawa, Kensuke, Hayashi, Shion, Tanabe, Yukitoshi, Kobayashi, Masahisa, Shimizu, Masaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society for Pediatric Endocrinology 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637416/ https://www.ncbi.nlm.nih.gov/pubmed/36405438 http://dx.doi.org/10.1297/cpe.2022-0018

Ejemplares similares

Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study
por: Roumie, Christianne L., et al.
Publicado: (2017)

Association Between Metformin and Sulfonylurea Monotherapies and Cancer Incidence: A Real-World Cohort Study in Shanghai, China
por: Ye, Jing-Hong, et al.
Publicado: (2019)

Efficacy and Safety of Ertugliflozin in Patients With Diabetes Mellitus Inadequately Controlled by Sulfonylurea Monotherapy: a Substudy of VERTIS CV
por: Strojek, Krzysztof, et al.
Publicado: (2021)

Perinatal management of a pregnant woman with COVID-19: A case report from Japan
por: Takahashi, Ken, et al.
Publicado: (2022)

A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy
por: Gitt, Anselm K, et al.
Publicado: (2015)

Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis
por: Qian, Dan, et al.
Publicado: (2018)

Monotherapy with Metformin versus Sulfonylureas and Risk of Cancer in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis
por: Mekuria, Abraham Nigussie, et al.
Publicado: (2019)

Sulfonylureas: Asset or liability?
por: Lakhani, Om J., et al.
Publicado: (2015)

Sulfonylureas at the Glomerular Battlefield
por: Kalra, Sanjay, et al.
Publicado: (2018)

Glucagon‐like peptide‐1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52‐week, randomized, multicenter trial
por: Seino, Yutaka, et al.
Publicado: (2011)

Sulfonylurea action re‐revisited
por: Seino, Susumu, et al.
Publicado: (2010)

Sulfonylureas and their use in clinical practice
por: Sola, Daniele, et al.
Publicado: (2015)

Influence of Hyperglycemia Associated with Enteral Nutrition on Mortality in Patients with Stroke
por: López-Gómez, Juan José, et al.
Publicado: (2019)

Time to Treatment Intensification in Patients Receiving DPP4 Inhibitors Versus Sulfonylureas as the First Add-On to Metformin Monotherapy: A Retrospective Cohort Study
por: Roberto, Giuseppe, et al.
Publicado: (2022)

Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus – International Task Force
por: Kalra, Sanjay, et al.
Publicado: (2018)

Long-term administration of Tetragenococcus halophilus No. 1 over generations affects the immune system of mice
por: Kotake, Kunihiko, et al.
Publicado: (2022)

Efficacy and Safety of Switching Latanoprost Monotherapy to Bimatoprost Monotherapy or Combination of Brinzolamide and Latanoprost
por: Imasawa, Mitsuhiro, et al.
Publicado: (2016)

Sulfonylureas: Assets in the past, present and future
por: Kalra, Sanjay, et al.
Publicado: (2015)

Sulfonylureas: Scoring beyond START STUDY
por: Shaikh, Altamash
Publicado: (2017)

Sulfonylurea and neuroprotection: The bright side of the moon
por: Hussien, Nawar R., et al.
Publicado: (2018)

The Place of Sulfonylureas in Guidelines: Why Are There Differences?
por: Amod, Aslam
Publicado: (2020)

Latest Evidence on Sulfonylureas: What’s New?
por: Leiter, Lawrence A.
Publicado: (2020)

Role of Octreotide in Sulfonylurea-Induced Hypoglycemia
por: Zafar, Sheema, et al.
Publicado: (2021)

Commentary on “Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus: International Task Force”
por: Singh, S. K.
Publicado: (2018)

Reduced vascular events in type 2 diabetes by biguanide relative to sulfonylurea: study in a Japanese Hospital Database
por: Tanabe, Makito, et al.
Publicado: (2015)

A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy
por: Orme, Michelle, et al.
Publicado: (2014)

Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: A meta-analysis
por: HOU, LIQIONG, et al.
Publicado: (2015)

Hypoglycemia Incidence Rates and Associated Health Care Costs in Patients with Type 2 Diabetes Mellitus Treated with Second-Line Linagliptin or Sulfonylurea After Metformin Monotherapy
por: Raju, Aditya, et al.
Publicado: (2016)

Sulfonylurea: Personalized Medicine for Type 2 Diabetes
por: Hwang, You-Cheol
Publicado: (2015)

Sulfonylurea-Induced Hypoglycemia in a Patient With Cirrhosis
por: Braet, Corey, et al.
Publicado: (2020)

The Place of Sulfonylureas in the Evolving Landscape of Combination Therapy
por: Yu, Miao
Publicado: (2020)

The Impact of Tirabrutinib Monotherapy for Bing-Neel Syndrome in Waldenström's Macroglobulinemia
por: Sekiguchi, Naohiro
Publicado: (2022)

Electronic medical records-based comparison of glycemic control efficacy between sulfonylureas and dipeptidyl peptidase-4 inhibitors added on to metformin monotherapy in patients with type 2 diabetes
por: Lee, Suhrin, et al.
Publicado: (2020)

Pioglitazone and sulfonylureas: effectively treating type 2 diabetes
por: Hanefeld, M
Publicado: (2007)

Diabetes mellitus in the young: Gliptins or sulfonylurea after metformin?
por: Muthukrishnan, J., et al.
Publicado: (2012)

Sulfonylurea Receptor 1 Expression in Human Cerebral Infarcts
por: Mehta, Rupal I., et al.
Publicado: (2013)

Modern Sulfonylureas Strike Back – Exploring the Freedom of Flexibility
por: Kalra, Sanjay, et al.
Publicado: (2018)

Solvent-Free Synthesis and Safener Activity of Sulfonylurea Benzothiazolines
por: Fu, Ying, et al.
Publicado: (2017)

Protonation and anion-binding properties of aromatic sulfonylurea derivatives
por: Barišić, D., et al.
Publicado: (2021)

Reduction of Sulfonylurea with the Initiation of Basal Insulin in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Undergoing Long-Term Sulfonylurea-Based Treatment
por: Yang, Yeoree, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vnkprtsnel0o0stf3gc508oada